However, findings of a recent prospective phase II trial in malignant pleural mesothelioma (MPM; COMMAND study), has since failed to confirm Merlin expression as a predictive biomarker of efficacy to a different FAK inhibitor, defactinib 132. This evidence concerns the gene PTK2 and malignant pleural mesothelioma.